Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice
Fan Zhang, Todd M. Hillhouse, Paige M Anderson, et al.
Pharmacology Biochemistry and Behavior (2021) Vol. 208, pp. 173228-173228
Closed Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Mechanisms of ketamine and its metabolites as antidepressants
Evan Hess, Lace M. Riggs, Michael Michaelides, et al.
Biochemical Pharmacology (2021) Vol. 197, pp. 114892-114892
Open Access | Times Cited: 117
NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine
Panos Zanos, Kyle A. Brown, Polymnia Georgiou, et al.
Journal of Neuroscience (2023) Vol. 43, Iss. 6, pp. 1038-1050
Open Access | Times Cited: 59
Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?
Marjorie R. Levinstein, Reece C. Budinich, Jordi Bonaventura, et al.
American Journal of Psychiatry (2025)
Closed Access | Times Cited: 2
The opioid system in depression
Luke A. Jelen, James Stone, Allan H. Young, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 140, pp. 104800-104800
Open Access | Times Cited: 53
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 33
Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats
Tommaso Di Ianni, Sedona N. Ewbank, Marjorie R. Levinstein, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 13
The endogenous opioid system in the medial prefrontal cortex mediates ketamine’s antidepressant-like actions
Cheng Jiang, Ralph Dileone, Christopher Pittenger, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
An integrative view on the cell-type-specific mechanisms of ketamine's antidepressant actions
Vern Lewis, Gareth M. Rurak, Natalina Salmaso, et al.
Trends in Neurosciences (2024) Vol. 47, Iss. 3, pp. 195-208
Open Access | Times Cited: 8
Ketamine’s mechanism of action with an emphasis on neuroimmune regulation: can the complement system complement ketamine’s antidepressant effects?
Brandi Quintanilla, Carlos A. Zarate, Anilkumar Pillai
Molecular Psychiatry (2024) Vol. 29, Iss. 9, pp. 2849-2858
Closed Access | Times Cited: 8
Ketamine treatment for anhedonia in unipolar and bipolar depression: a systematic review
Aleksander Kwaśny, Julia Kwaśna, Alina Wilkowska, et al.
European Neuropsychopharmacology (2024) Vol. 86, pp. 20-34
Closed Access | Times Cited: 6
Ketamine and Major Ketamine Metabolites Function as Allosteric Modulators of Opioid Receptors
Ivone Gomes, Achla Gupta, Elyssa B. Margolis, et al.
Molecular Pharmacology (2024) Vol. 106, Iss. 5, pp. 240-252
Closed Access | Times Cited: 5
Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors
Hildegard A. Wulf, Caroline A. Browne, Carlos A. Zarate, et al.
Psychopharmacology (2022) Vol. 239, Iss. 7, pp. 2309-2316
Closed Access | Times Cited: 19
Differential effects of statins on the anti-dyskinetic activity of sub-anesthetic ketamine
Mitchell J. Bartlett, Carolyn J. Stopera, Stephen L. Cowen, et al.
Neuroscience Letters (2025) Vol. 848, pp. 138114-138114
Open Access
Assessment of complement cascade components in patients with major depressive disorder
Brandi Quintanilla, Dede Greenstein, Ashutosh Tripathi, et al.
Brain Behavior and Immunity (2025)
Closed Access
Increased Sensitivity to Psychomotor Effects of Ketamine Enantiomers in the Wistar-Kyoto Depression Model
Kristian Elersič, Anamarija Banjac, Marko Z̆ivin, et al.
Journal of Psychiatric Research (2025) Vol. 184, pp. 307-317
Open Access
Ketamine evokes acute behavioral effects via μ-opioid receptor expressing neurons of the central amygdala
Matthew B. Pomrenze, Sam Vaillancourt, Pierre Llorach, et al.
Biological Psychiatry (2025)
Closed Access
Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine
Miroslav Adžić, Iva Lukić, Miloš Mitić, et al.
Life Sciences (2023) Vol. 326, pp. 121803-121803
Closed Access | Times Cited: 9
The Melanocortin System: A Promising Target for the Development of New Antidepressant Drugs
Dmitrii D. Markov, О. В. Долотов, И. А. Гривенников
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6664-6664
Open Access | Times Cited: 7
Short-term ketamine use in bipolar depression: a review of the evidence for short-term treatment management
Alina Wilkowska, Wiesław Jerzy Cubała
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 7
Treatment-Resistant Depression (TRD): Is the Opioid System Involved?
Shaul Schreiber, Lee Keidan, Chaim G. Pick
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 11142-11142
Open Access | Times Cited: 5
Opioid Mechanisms and the Treatment of Depression
Luke A. Jelen, Allan H. Young, Mitul A. Mehta
Current topics in behavioral neurosciences (2023), pp. 67-99
Closed Access | Times Cited: 4
Opioid receptor expressing neurons of the central amygdala gate behavioral effects of ketamine in mice
Matthew B. Pomrenze, Sam Vaillancourt, Pierre Llorach, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Ketamine and hydroxynorketamine as novel pharmacotherapies for the treatment of Opioid-Use Disorders
Onisiforou Anna, Andria Michael, Markos Apostolakis, et al.
Biological Psychiatry (2024)
Open Access | Times Cited: 1
Effects of ketamine optical isomers, fluoxetine and naloxone on timing in differential reinforcement of low-rate response (DRL) 72-s task in rats
Natalia Malikowska‐Racia, Joanna Gołębiowska, Agnieszka Nikiforuk, et al.
European Neuropsychopharmacology (2022) Vol. 67, pp. 37-52
Open Access | Times Cited: 7
κ-Opioid Receptor Plasma Levels Are Associated With Sex and Diagnosis of Major Depressive Disorder But Not Response to Ketamine
Brandi Quintanilla, Gustavo C. Medeiros, Dede Greenstein, et al.
Journal of Clinical Psychopharmacology (2023) Vol. 43, Iss. 2, pp. 89-96
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top